Corvus Pharmaceuticals issues Q2 2026 results release
Corvus Pharmaceuticals, Inc. reported that it issued a press release on August 6, 2026 covering its financial results for the three and six months ended June 30, 2026, its financial position as of June 30, 2026, and a broader business update.
Rhea-AI Filing Summary
Corvus Pharmaceuticals, Inc. reported that it issued a press release on August 6, 2026 covering its financial results for the three and six months ended June 30, 2026, its financial position as of June 30, 2026, and a broader business update.
The press release is furnished as Exhibit 99.1. Corvus states that the information related to these results and the exhibit is being furnished, not filed, for purposes of Section 18 of the Securities Exchange Act of 1934 and will only be incorporated into other securities law filings by specific reference.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Press release date: August 6, 2026
Reporting period: three and six months ended June 30, 2026
Financial position date: June 30, 2026
3 metrics
Press release date
August 6, 2026
Date Corvus issued the press release with financial results and business update
Reporting period
three and six months ended June 30, 2026
Period covered by the financial results described in the press release
Financial position date
June 30, 2026
Date as of which the company’s financial position is described
Key Terms
Results of Operations and Financial Condition, Emerging growth company, Section 18 of the Securities Exchange Act of 1934, Inline XBRL
4 terms
Results of Operations and Financial Condition financial
"Item 2.02. Results of Operations and Financial Condition."
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Section 18 of the Securities Exchange Act of 1934 regulatory
"shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934"
Inline XBRL technical
"Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
Earnings Snapshot
three and six months ended June 30, 2026
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Corvus Pharmaceuticals (CRVS) disclose in its latest 8-K?
Corvus Pharmaceuticals disclosed that it issued a press release on August 6, 2026 with financial results for the three and six months ended June 30, 2026, its financial position as of that date, and a business update.
Which reporting period does Corvus Pharmaceuticals (CRVS) cover in this update?
The update covers Corvus Pharmaceuticals’ financial results for the three and six months ended June 30, 2026, as well as its financial position as of June 30, 2026, according to the company’s press release.
What is Exhibit 99.1 in Corvus Pharmaceuticals’ (CRVS) 8-K?
Exhibit 99.1 is the press release of Corvus Pharmaceuticals dated August 6, 2026 that contains its quarterly and year-to-date financial results, financial position as of June 30, 2026, and an accompanying business update.
Is Corvus Pharmaceuticals’ (CRVS) earnings information considered filed with the SEC?
Corvus specifies that the earnings information and Exhibit 99.1 are furnished, not filed, under Section 18 of the Exchange Act, and are only incorporated into other securities filings if expressly referenced.
Does the Corvus Pharmaceuticals (CRVS) 8-K include a business update?
Yes. Corvus states that the August 6, 2026 press release provides a business update in addition to presenting financial results for the three and six months ended June 30, 2026 and its financial position as of that date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
